



Saya, UCB researcher

UCB in the U.S.

**Inspired by patients
Driven by science**

About UCB

UCB is a global biopharmaceutical company focused on severe diseases that have significant unmet needs. By putting patients at the heart of everything we do, we enable people to live their best lives, delivering impactful solutions patients value.

At UCB, we come together every day to work, laser-focused, on a simple question: How will this create value for people living with severe diseases? Patient value is not just what we say, but how we live. It is our culture of care, embodied by our patient value strategy. That's because how we do business – from discovery to development to delivery – has been transformed and redesigned around the patient and their individual experience. Patients are at the heart of everything we do, inspiring us, driving our scientific discovery, and leading us to rethink the patient experience. By fulfilling our commitment, driving innovation, and providing patients a meaningful experience, more impactful solutions are on the horizon.

With a team of approximately 7,500 employees and operations in nearly 40 countries, we are a global biopharmaceutical company investing about a quarter of our revenue in cutting-edge scientific research to meet unmet patient needs. Global headquarters are

Approximately **1,400 employees** in the **United States** including research and development and operations


in Brussels, Belgium, with U.S. headquarters in Atlanta, Georgia. Additional U.S. sites include global clinical development in Raleigh, North Carolina, our policy office in Washington, D.C., and research supporting UCB's pipeline in

Boston, Massachusetts and Seattle, Washington. We also have an office in Durham, North Carolina as part of our acquisition of Element Genomics.

HOW WE DELIVER VALUE IN THE U.S.

As UCB's largest affiliate, we have around 1,400 U.S.-based employees.

- 2019 U.S. Economic Footprint: **\$645 million**
- **7 UCB offices** across Georgia, Massachusetts, North Carolina, Washington, and Washington, D.C.
- **6% increase** in U.S. employees from 2018 to 2019
- **130** active U.S. Clinical Studies
- Globally, we invest **about a quarter** of our revenue every year in R&D
- In the U.S., about **23%** of our employees are dedicated to R&D



DISEASE AREAS

At UCB, we want to help people live their best lives, whatever that means for them. We're focused on severe, chronic neurological and immunological conditions. And we're blazing a path integrating new technologies, like machine learning and data analytics, into how we work today to unlock a healthier tomorrow.

Beyond medicines, we support patients in the community through additional services and with online resources for patients and their families.

1994

UCB entered the U.S. market

2000

Launched **KEPPRA®** (levetiracetam)

2008

Launched UCB's first biologic, **CIMZIA®** (certolizumab pegol)

2010

UCB exited primary care market to focus on severe diseases in specialty markets

2014

Received additional indication for **VIMPAT®**

2017

Received additional indication for **BRIVIACT®** and **VIMPAT®**. Expanded our basic science capabilities in the U.S. with the acquisition of Beryllium Discovery

2019

Received additional indication for **CIMZIA®**. Launched **NAYZILAM®** (midazolam) CIV nasal spray.

1996

Launched **ZYRTEC®** (cetirizine HCl) in co-promotion with Pfizer

2004 & 2006

Acquired Celltech Pharmaceuticals and Schwarz Pharma AG

2007

Launched **NEUPRO®** (rotigotine transdermal system)

2009

Launched **VIMPAT®** (lacosamide) CV

2013

Received additional indications for **CIMZIA®**

2016

Launched **BRIVIACT®** (brivaracetam) CV


2018

Received label update for **CIMZIA®**. Received approval for expanded population for **BRIVIACT®**. Expanded our R&D footprint in the U.S. with the acquisition of Element Genomics

Please see full prescribing information for products mentioned above, including boxed warning for CIMZIA, regarding serious infections including tuberculosis and malignancies, and boxed warning for NAYZILAM, regarding risk for respiratory depression, at UCB-USA.com/Innovation/Products.

U.S. Innovation

Our approach to innovation keeps patients at the center. We use patient insights to inform our science to build solutions to deliver to patients. Innovation is ongoing as we continue to search for solutions to meet the unmet needs of patients.



Our future has never been brighter and the opportunities to provide patients with solutions they value has never been more urgent. By fulfilling our commitment, driving innovation, and providing patients a meaningful experience, solutions are on the horizon to help more patients managing severe diseases live their best lives.

As long as there are unmet needs, our mission continues. We are inspired by patients and driven by science to deliver what patients value.

For More Information:

www.ucb-usa.com

 [@UCBUSBA](https://twitter.com/UCBUSBA)

 facebook.com/UCBbiopharma

 linkedin.com/company/ucb-pharma

 Inspired by **patients**.
Driven by **science**.

VIMPAT® is a registered trademark under license from Harris FRC Corporation. BRIVIACT®, CIMZIA®, KEPPRA®, NAYZILAM®, and NEUPRO® are registered trademarks of the UCB Group of Companies. All other trademarks are the property of their respective holders. ©2020 UCB, Inc. Smyrna, GA 30080. All rights reserved. Printed in the USA. US-P-BR-EPOS-2000101